Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
In Iran all transfusion services are concentrated under authority of one public and centralized transfusion organization which has created the opportunity of using plasma produced in its blood centers for fractionation. In 2008 voluntary and non remunerated Iranian donors donated 1.8 million units of blood. This indicates a 25/1000 donation index. After responding to the needs for fresh plasma and cryoprecipitate each year about 150000 L of recovered plasma are reserved for fractionation. In an attempt to improve both blood safety profile and availability and affordability of plasma derived medicines, Iran's national transfusion service has entered into a contract fractionation agreement for surplus of plasma produced from donated blood by voluntary non remunerated donors. In order to ensure safety of product produced, Iran has chosen to collaborate with international fractionators based in highly regulated countries. The main objective of this study was to evaluate the impact of contract plasma fractionation on the affordability of the plasma derived medicines in Iran. During 2006-2008, Iran's contract fractionation project was able to produce 46%, 18% and 6% of IVIG, Albumin and FVIII consumed in Iran's market, respectively. In contrary to IVIG and Albumin, due to fairly high consumption of FVIII in Iran, the role of fractionation project in meeting the needs to FVIII was not substantial. However, Iran's experience has shown that contract plasma fractionation, through direct and indirect effects on price of plasma derived medicines, could substantially improve availability and affordability of such products in national health care system.
Cheraghali
A M
AM
Iranian Blood Transfusion Organization Research Center and Chemical Injury Research Center, University of Baqiyatallah Medical Sciences, Tehran, Iran. Cheraghali@ibto.ir
Aboofazeli
R
R
D001771:Blood Banks / Q000191:economics*; D001798:Blood Proteins / Q000191:economics / Q000302:isolation & purification / Q000627:therapeutic use*; D001803:Blood Transfusion; D004467:Economics; D005169:Factor VIII / Q000302:isolation & purification; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000302:isolation & purification; D007492:Iran; D009313:National Health Programs; D010949:Plasma / Q000737:chemistry*; D012709:Serum Albumin / Q000302:isolation & purification; D000094902:Blood Banking / Q000379:methods*
D001798:Blood Proteins; D016756:Immunoglobulins, Intravenous; D012709:Serum Albumin; D005169:Factor VIII